FY2024 EPS Estimate for Pyxis Oncology Reduced by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – William Blair cut their FY2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Tuesday, November 12th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($1.02) per share for the year, down from their previous forecast of ($1.00). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

A number of other equities research analysts have also recently commented on the company. Stephens initiated coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price on the stock. Stifel Nicolaus began coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.57.

Pyxis Oncology Price Performance

PYXS opened at $4.28 on Friday. The company has a fifty day moving average of $3.66 and a two-hundred day moving average of $3.66. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently made changes to their positions in PYXS. Fullcircle Wealth LLC purchased a new stake in shares of Pyxis Oncology during the second quarter worth approximately $40,000. Intech Investment Management LLC purchased a new stake in shares of Pyxis Oncology during the third quarter worth $55,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology in the third quarter valued at about $58,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pyxis Oncology in the second quarter valued at about $65,000. Finally, MetLife Investment Management LLC lifted its stake in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares in the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.